• Corpus ID: 6169824

Large Molecule Therapeutics Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD 2 Using an IgG-scFv Bispeci fi c Antibody with High Af fi nity for GD 2 and DOTA Metal Complex

  title={Large Molecule Therapeutics Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD 2 Using an IgG-scFv Bispeci fi c Antibody with High Af fi nity for GD 2 and DOTA Metal Complex},
  author={Sarah M. Cheal and Hong Xu and Hong-fen Guo and Pat Zanzonico and Steven M. Larson and Nai-Kong V. Cheung},
Bispecific antibodies (BsAb) haveproven to beuseful targeting vectors for pretargeted radioimmunotherapy (PRIT). We sought to overcome key PRIT limitations such as high renal radiation exposure and immunogenicity (e.g., of streptavidin–antibody fusions), to advance clinical translation of this PRIT strategy for diasialoganglioside GD2-positive [GD2(þ)] tumors. For this purpose, an IgG-scFv BsAbwas engineered using the sequences for the anti-GD2humanizedmonoclonal antibodyhu3F8 andC825, amurine… 

Figures and Tables from this paper


Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2.
  • N. Cheung, S. Modak, S. Larson
  • Biology, Chemistry
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 2004
Improvement in the T/NT ratio using pretargeting strategy may increase the efficacy and safety of scFv-based approaches in cancer therapy and a large repertoire of agents can potentially be explored.
Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy.
The results indicate that pretargeting 90Y hapten-specific mAb for radioimmunotherapy has considerable promise.
A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance.
A pre-targeted radiotherapeutic and substantial reduction in the radioactive exposure to the bone marrow should enhance the therapeutic potential of RIT.
Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody
This bsMAb-pretargeting procedure significantly improves the therapeutic response of targeted radionuclides in non-Hodgkin's lymphoma, warranting further development of this method of radioimmunotherapy.
Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging.
Effect of Small-Molecule–Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody
A simple mathematical model of tumor targeting is derived using measurable parameters that correlates well with experimental observations and relations derived from the model are used to develop design criteria for the future development of small-molecule agents for targeted cancer therapeutics.
89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo
It is demonstrated that 89Zr-DFO–labeled mAbs show exceptional promise as radiotracers for immunoPET of human cancers and can be used to delineate and quantify PSMA-positive prostate tumors in vivo.
Biodistribution and Clearance of Small Molecule Hapten Chelates for Pretargeted Radioimmunotherapy
A group of DOTA-based haptens that exhibit rapid clearance and exceptionally low whole-body retention 4 h postinjection are presented that are likely to be ideal hapten for pretargeted radioimmunotherapy.
A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts.
It is suggested that anti-CD20 pretargeting shows great promise for improving current therapeutic options for B-cell lymphomas and warrants further preclinical and clinical testing.
Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo
Humanization of m3F8 produced next generation anti-GD2 antibodies with substantially more potent ADCC in vitro and anti-tumor activity in vivo, which may be clinically more effective, while minimizing pain and HAMA side effects.